In the mice with mild (3-week) NASH, CU06-1004 treatment led to significantly decreased mRNA expression of tumor necrosis factor-α (TNF-α) compared with the CD group (Fig 3A). Here, TNF is linked to metabolic dysfunction-associated steatohepatitis.